Li Xing, Zhao Rui, Lv Hai-Feng, Ying Miao-Fa, Jiang Zhou
Department of Pharmacy, Qiantang Campus, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang Uni-versity, Hangzhou, China.
School of Pharmacy, Hangzhou Medical College, Hangzhou, China.
Asia Pac J Clin Nutr. 2023;32(1):77-84. doi: 10.6133/apjcn.202303_32(1).0012.
Conventional soybean oil-based intravenous lipid emulsions (SO-ILEs) have high polyunsaturated fatty acid (PUFA) contents and phytosterols that may have adverse effects in preterm infants. Recently, the multi-oil-based intravenous lipid emulsion (MO-ILE), SMOFlipid, has been widely utilized in the neonatal intensive care unit (NICU), but significant benefits over SO-ILEs in low gestational age neonates have yet to be demonstrated. This study was performed to compare the effects of the SO-ILE, Intralipid, and the MO-ILE, SMOFlipid, on neonatal health outcomes in preterm infants.
We performed a retrospective review of preterm infants born at gestational week (GW) <32 receiving parenteral nutrition for longer durations (≥14 d) in the NICU between 2016 and 2021. The primary aim of this study was to investigate differences in morbidity between preterm infants receiving SMOFlipid and Intralipid.
A total of 262 preterm infants were included in the analysis, with 126 receiving SMOFlipid and 136 receiving Intralipid. The SMOFlipid group had lower rates of ROP (23.8% vs 37.5%, respectively; p=0.017), although the rate of ROP was not different in multivariate regression analysis. The length of hospi-tal stay was significantly shorter in the SMOFlipid than SO-ILE group (median [IQR]=64.8 [37] vs 72.5 [49] days; p<0.001).
The use of SMOFlipid as the lipid emulsion was associated with higher clinical efficacy than SO-ILE in preterm infants.
传统的大豆油基静脉脂质乳剂（SO-ILEs）含有高含量的多不饱和脂肪酸（PUFA）和植物甾醇，可能对早产儿产生不良影响。最近，多油基静脉脂质乳剂（MO-ILE）SMOFlipid已在新生儿重症监护病房（NICU）中广泛应用，但在低胎龄新生儿中相对于SO-ILEs的显著益处尚未得到证实。本研究旨在比较SO-ILE（英脱利匹特）和MO-ILE（SMOFlipid）对早产儿新生儿健康结局的影响。
我们对2016年至2021年间在NICU中孕周（GW）<32周且接受较长时间（≥14天）肠外营养的早产儿进行了回顾性研究。本研究的主要目的是调查接受SMOFlipid和英脱利匹特的早产儿在发病率上的差异。
共有262例早产儿纳入分析，其中126例接受SMOFlipid，136例接受英脱利匹特。SMOFlipid组的ROP发生率较低（分别为23.8%和37.5%；p=0.017），尽管在多因素回归分析中ROP发生率无差异。SMOFlipid组的住院时间明显短于SO-ILE组（中位数[四分位间距]=64.8[37]天 vs 72.5[49]天；p<0.001）。
在早产儿中，使用SMOFlipid作为脂质乳剂比SO-ILE具有更高的临床疗效。
